MA51155A - Compositions comprenant des polyribonucléotides circulaires et leurs utilisations - Google Patents

Compositions comprenant des polyribonucléotides circulaires et leurs utilisations

Info

Publication number
MA51155A
MA51155A MA051155A MA51155A MA51155A MA 51155 A MA51155 A MA 51155A MA 051155 A MA051155 A MA 051155A MA 51155 A MA51155 A MA 51155A MA 51155 A MA51155 A MA 51155A
Authority
MA
Morocco
Prior art keywords
compositions consisting
circular polyribonucleotides
polyribonucleotides
circular
compositions
Prior art date
Application number
MA051155A
Other languages
English (en)
Inventor
Catherine Cifuentes-Rojas
Boer Alexandra Sophie De
Avak Kahvejian
Michael Donato Melfi
Ki Young Paek
Nicholas Mccartney Plugis
Morag Helen Stewart
Sebastian Trousil
Erica Gabrielle Weistein
Original Assignee
Flagship Pioneering Innovations Vi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations Vi Llc filed Critical Flagship Pioneering Innovations Vi Llc
Publication of MA51155A publication Critical patent/MA51155A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA051155A 2017-12-15 2018-12-14 Compositions comprenant des polyribonucléotides circulaires et leurs utilisations MA51155A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762599547P 2017-12-15 2017-12-15
US201862676688P 2018-05-25 2018-05-25

Publications (1)

Publication Number Publication Date
MA51155A true MA51155A (fr) 2020-10-21

Family

ID=66820668

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051155A MA51155A (fr) 2017-12-15 2018-12-14 Compositions comprenant des polyribonucléotides circulaires et leurs utilisations

Country Status (13)

Country Link
US (9) US12357653B2 (fr)
EP (1) EP3724208A4 (fr)
JP (3) JP2021508490A (fr)
KR (1) KR20200127152A (fr)
CN (3) CN120774994A (fr)
AU (2) AU2018385757B2 (fr)
BR (1) BR112020011670A2 (fr)
CA (1) CA3084824A1 (fr)
IL (2) IL275205B2 (fr)
MA (1) MA51155A (fr)
MX (1) MX2020006150A (fr)
SG (1) SG11202005060YA (fr)
WO (1) WO2019118919A1 (fr)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51155A (fr) 2017-12-15 2020-10-21 Flagship Pioneering Innovations Vi Llc Compositions comprenant des polyribonucléotides circulaires et leurs utilisations
BR112020024292A2 (pt) * 2018-06-06 2021-03-02 Massachusetts Institute Of Technology rna circular para translação em células eucarióticas
CN121081491A (zh) 2019-03-04 2025-12-09 旗舰创业创新第六有限责任公司 环状多核糖核苷酸及其药物组合物
CN111718929B (zh) * 2019-03-20 2022-10-18 中国科学院上海营养与健康研究所 利用环形rna进行蛋白翻译及其应用
CN114207134B (zh) * 2019-03-25 2024-11-15 俄亥俄州国家创新基金会 工程化的mRNA序列及其用途
EP3946466A2 (fr) 2019-03-25 2022-02-09 Flagship Pioneering Innovations VI, LLC Compositions comprenant des polyribonucléotides circulaires modifiés et utilisations associées
IL288284B2 (en) 2019-05-22 2024-06-01 Massachusetts Inst Technology Circular rna compositions and methods
CA3140205A1 (fr) * 2019-06-14 2020-12-17 Alexandra Sophie DE BOER Arn circulaires pour therapie cellulaire
AU2020296190A1 (en) 2019-06-19 2022-01-06 Flagship Pioneering Innovations Vi, Llc Methods of dosing circular polyribonucleotides
WO2020257730A1 (fr) 2019-06-19 2020-12-24 Flagship Pioneering Innovations Vi, Llc Compositions comprenant des polyribonucléotides circulaires pour la modulation de protéine et leurs utilisations
CN112662659B (zh) * 2019-10-15 2022-08-19 武汉核圣生物技术有限公司 一种普适性的mRNA体外环化方法
WO2021081261A1 (fr) * 2019-10-22 2021-04-29 The Regents Of The University Of California Modulation de la traduction des récepteurs des cellules immunitaires modifiées à l'aide d'éléments de séquence non codants
AU2020395111A1 (en) * 2019-12-02 2022-06-02 The Regents Of The University Of California Engineering circular guide RNAs
WO2021113777A2 (fr) 2019-12-04 2021-06-10 Orna Therapeutics, Inc. Méthodes et compositions d'arn circulaire
US20230181620A1 (en) * 2020-01-29 2023-06-15 Flagship Pioneering Innovations Vi, Llc Compositions for translation and methods of use thereof
EP4096681A1 (fr) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Administration de compositions comprenant des polyribonucléotides circulaires
MX2022011677A (es) * 2020-03-20 2023-01-11 Orna Therapeutics Inc Composiciones y métodos de arn circular.
US20240042015A1 (en) * 2020-05-19 2024-02-08 Orna Therapeutics, Inc. Circular rna compositions and methods
CA3179444A1 (fr) 2020-05-20 2021-11-25 Avak Kahvejian Compositions immunogenes et leurs utilisations
MX2022014653A (es) 2020-05-20 2023-02-16 Flagship Pioneering Innovations Vi Llc Composiciones de antigeno de coronavirus y sus usos.
EP4153152A1 (fr) * 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Compositions et procédés de production d'anticorps polyclonaux humains
CN111733243A (zh) * 2020-06-29 2020-10-02 中山大学孙逸仙纪念医院 一种提高CircRNA检测准确率的方法
KR20230030618A (ko) * 2020-07-01 2023-03-06 엘레바테바이오 테크놀로지스, 인코포레이티드 원형 rna를 사용하는 세포 리프로그래밍을 위한 조성물 및 방법
MX2023001782A (es) 2020-08-12 2023-05-22 Actym Therapeutics Inc Vacunas, productos terapéuticos y plataformas de administración de arn a base de bacterias inmunoestimuladoras.
JP2023542492A (ja) * 2020-09-03 2023-10-10 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 免疫原性組成物及びその使用
KR20230124682A (ko) 2020-12-23 2023-08-25 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Rna를 봉입하는 아넬로바이러스 캡시드의 시험관 내어셈블리
CN112562788B (zh) * 2020-12-28 2022-06-28 上海交通大学 一种环状rna-rna结合蛋白关系预测模型构建方法
CN115997018A (zh) 2021-03-10 2023-04-21 尔知渃米斯股份有限公司 自身环化rna构建体
WO2022204460A1 (fr) 2021-03-26 2022-09-29 Flagship Pioneering Innovations Vii, Llc Compositions et procédés de production de polyribonucléotides circulaires
WO2022204464A1 (fr) 2021-03-26 2022-09-29 Flagship Pioneering Innovations Vii, Llc Production de polyribonucléotides circulaires dans un système eucaryote
TW202305130A (zh) 2021-03-26 2023-02-01 美商旗艦先鋒創新有限責任(Vii)公司 原核系統中環狀多核糖核苷酸之產生
CA3214085A1 (fr) 2021-03-31 2022-10-06 Darby Rye Schmidt Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
US20240240218A1 (en) 2021-05-18 2024-07-18 Flagship Pioneering Innovations Vi, Llc Methods of enriching for circular polyribonucleotides
CN117425735A (zh) 2021-05-18 2024-01-19 旗舰创业创新第六有限责任公司 富集环状多核糖核苷酸的方法
WO2023288287A2 (fr) * 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Constructions d'arn synthétiques, persistants et procédés d'utilisation pour le rajeunissement de cellules et pour le traitement
WO2023288288A1 (fr) 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Constructions d'arn synthétiques persistants dotées d'un mécanisme de mise en marche/arrêt pour l'expression régulée et procédés d'utilisation
KR20240047986A (ko) 2021-07-27 2024-04-12 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 가공을 위한 디바이스, 시스템 및 방법
CN118317944A (zh) 2021-09-14 2024-07-09 雷纳嘉德医疗管理公司 非环状脂质及其使用方法
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
EP4464783A3 (fr) 2021-09-17 2025-01-22 Flagship Pioneering Innovations VI, LLC Compositions et procédés de production de polyribonucléotides circulaires
TW202322826A (zh) 2021-10-18 2023-06-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物及方法
US20250027108A1 (en) * 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
EP4429682A2 (fr) 2021-11-09 2024-09-18 Actym Therapeutics, Inc. Bactéries immunostimulatrices pour convertir des macrophages en un phénotype pouvant être traité, et diagnostic compagnon pour identifier des sujets pour un traitement
US20250032604A1 (en) 2021-11-24 2025-01-30 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
WO2023096990A1 (fr) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Compositions immunogènes de coronavirus et leurs utilisations
KR20240125931A (ko) 2021-11-24 2024-08-20 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 수두-대상포진 바이러스 면역원 조성물 및 이의 용도
KR102488280B1 (ko) * 2021-11-25 2023-01-16 주식회사 뉴클릭스바이오 신규한 부목 dna 및 이의 용도
WO2023115013A1 (fr) 2021-12-17 2023-06-22 Flagship Pioneering Innovations Vi, Llc Procédés d'enrichissement en arn circulaire dans des conditions de dénaturation
CN118679254A (zh) 2021-12-22 2024-09-20 旗舰创业创新六公司 用于纯化多核糖核苷酸的组合物和方法
MX2024007870A (es) 2021-12-23 2024-08-15 Flagship Pioneering Innovations Vi Llc Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
WO2023122752A1 (fr) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Lipides contraints et procédés d'utilisation associés
CN118451182A (zh) * 2022-01-28 2024-08-06 北京昌平实验室 环状rna疫苗及其使用方法
AU2023251104A1 (en) 2022-04-07 2024-10-17 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
JP2025525778A (ja) 2022-08-01 2025-08-07 フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー 免疫調節タンパク質及び関連方法
KR20240034676A (ko) 2022-09-06 2024-03-14 알지노믹스 주식회사 자가 환형화 rna 구조체
US20260078370A1 (en) 2022-09-06 2026-03-19 Rznomics Inc. Self-circularization rna structure
WO2024077191A1 (fr) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer
CN120513299A (zh) 2022-10-31 2025-08-19 旗舰创业创新第六有限责任公司 用于纯化多核糖核苷酸的组合物和方法
AR131008A1 (es) 2022-11-08 2025-02-05 Flagship Pioneering Innovations Vi Llc Composiciones y métodos para producir polirribonucleótidos circulares
TW202430636A (zh) * 2022-11-08 2024-08-01 財團法人國家衛生研究院 環狀rna及其製備方法和應用
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任(Vii)公司 用於將治療劑遞送至骨之組成物和方法
KR102584714B1 (ko) 2022-12-28 2023-10-10 라이보텍(주) 덤벨 구조를 이용한 원형 rna 제조 방법
US20240252520A1 (en) 2023-01-09 2024-08-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic agents and their use for treating chronic wounds
WO2024151687A1 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Commutateurs génétiques et leur utilisation dans le traitement du cancer
WO2024151673A2 (fr) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Molécules d'acide nucléique recombinant et leur utilisation dans la cicatrisation de plaies
EP4648794A2 (fr) 2023-01-09 2025-11-19 Flagship Pioneering Innovations VII, LLC Vaccins et procédés associés
KR102581491B1 (ko) * 2023-01-20 2023-09-25 한국과학기술원 mRNA의 세포내 안정성과 생합성을 향상시키는 래리엇 캡 구조의 RNA, 및 이의 용도
AU2024212425A1 (en) 2023-01-27 2025-08-07 Sail Biomedicines, Inc. A modified lipid composition and uses thereof
EP4654953A1 (fr) * 2023-01-27 2025-12-03 The Methodist Hospital Procédés de fabrication et d'isolement d'arn circulaires et de compositions d'arn circulaire
TW202438515A (zh) 2023-02-06 2024-10-01 美商旗艦先鋒創新有限責任(Vii)公司 免疫調節組合物及相關方法
WO2024192291A1 (fr) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Administration de systèmes d'édition de gènes et leurs procédés d'utilisation
WO2024192422A1 (fr) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Compositions immunogènes et leurs utilisations
EP4680595A2 (fr) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Nanoparticules lipidiques comprenant des molécules d'arn codant destinées à être utilisées dans l'édition génique et en tant que vaccins et agents thérapeutiques
JP2026509462A (ja) 2023-03-15 2026-03-19 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー ポリリボヌクレオチドを含む組成物及びその使用
WO2024220712A2 (fr) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Compositions vaccinales
WO2024220752A2 (fr) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Compositions thérapeutiques à arn
WO2024220625A1 (fr) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Administration de polynucléotides à partir de nanoparticules lipidiques comprenant de l'arn et des lipides ionisables
KR20240170771A (ko) * 2023-05-26 2024-12-04 삼성바이오로직스 주식회사 2차 또는 3차 구조를 갖는 폴리 a 테일을 포함하는 신규 핵산 구조체 및 이의 용도
WO2025006684A1 (fr) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Polyribonucléotides circulaires codant pour des polypeptides antifusogènes
WO2025042786A1 (fr) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprenant des polyribonucléotides circulaires et leurs utilisations
AU2024335327A1 (en) 2023-09-01 2026-03-26 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025081042A1 (fr) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Système d'édition de précision basé sur un modèle de nickase-rétron et méthodes d'utilisation
WO2025106930A1 (fr) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Polyribonucléotides circulaires codant le peptide 2 de type glucagon (glp-2) et leurs utilisations
WO2025106915A1 (fr) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Polyribonucléotides circulaires codant le peptide 1 de type glucagon (glp-1) et leurs utilisations
WO2025128871A2 (fr) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Nanoparticules lipidiques comprenant des molécules d'arn codant destinées à être utilisées dans l'édition de gènes et en tant que vaccins et agents thérapeutiques
WO2025147583A1 (fr) 2024-01-05 2025-07-10 Sail Biomedicines, Inc. Ligands pd-1 modifiés
WO2025155753A2 (fr) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Système, guides et procédés d'édition de gènes améliorés
WO2025160334A1 (fr) 2024-01-26 2025-07-31 Flagship Pioneering Innovations Vii, Llc Protéines inhibitrices d'immunorécepteurs et procédés associés
WO2025174765A1 (fr) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Nanoparticules lipidiques comprenant des molécules d'arn codant destinées à être utilisées dans l'édition génique et comme vaccins et agents thérapeutiques
CN120501756A (zh) * 2024-02-18 2025-08-19 中山大学孙逸仙纪念医院 一种药物组合物及其应用
WO2025179198A1 (fr) 2024-02-23 2025-08-28 Sail Biomedicines, Inc. Polyribonucléotides circulaires et arn linéaires non modifiés à immunogénicité réduite
CN118374525B (zh) * 2024-04-22 2025-02-25 广州派真生物技术有限公司 一种环状rna转录载体及其制备方法和应用
US20250353881A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245111A1 (fr) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Protéines de ciblage d'immunorécepteurs et procédés associés
WO2026006593A1 (fr) 2024-06-28 2026-01-02 Orna Therapeutics, Inc. Sites d'entrée interne des ribosomes synthétiques

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JPH06500014A (ja) 1990-07-25 1994-01-06 シンジーン,インコーポレイテッド 多数の核酸相補体を生成させる環状伸長法
US5426180A (en) 1991-03-27 1995-06-20 Research Corporation Technologies, Inc. Methods of making single-stranded circular oligonucleotides
US5877160A (en) 1991-05-31 1999-03-02 Genta Incorporated Compositions and methods of treatment of androgen-associated baldness using antisense oligomers
ATE148889T1 (de) 1991-09-18 1997-02-15 Affymax Tech Nv Verfahren zur synthese der verschiedenen sammlungen von oligomeren
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
JPH07502898A (ja) 1992-01-13 1995-03-30 デューク・ユニバーシティー 酵素rna分子
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
EP0585597B1 (fr) 1992-08-04 1999-05-12 Deutsche Thomson-Brandt Gmbh Transformateur de ligne à haute tension pour un récepteur de télévision
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5721099A (en) 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
US5440016A (en) 1993-06-18 1995-08-08 Torrey Pines Institute For Molecular Studies Peptides of the formula (KFmoc) ZZZ and their uses
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5688997A (en) 1994-05-06 1997-11-18 Pharmacopeia, Inc. Process for preparing intermediates for a combinatorial dihydrobenzopyran library
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5688696A (en) 1994-12-12 1997-11-18 Selectide Corporation Combinatorial libraries having a predetermined frequency of each species of test compound
ES2174075T3 (es) 1995-06-21 2002-11-01 Martek Biosciences Corp Librerias combinatorias de compuestos bioquimicos marcados y metodos para producir las mismas.
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
CA2158237A1 (fr) 1995-09-13 1997-03-14 Paolo Favaretto Siege avec dossier pivotant
US5731423A (en) 1996-03-21 1998-03-24 Transcell Technologies, Inc. Process for preparing sulfoxides
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
DE10132780A1 (de) 2001-07-06 2003-01-16 Icon Genetics Ag Plastidäre Genexpression über autonom replizierende Vektoren
EP2428571B1 (fr) 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Molécules de micro ARN
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US20050074804A1 (en) 2003-09-26 2005-04-07 Youxiang Wang Amplification of polynucleotide sequences by rolling circle amplification
AU2005222965B8 (en) 2004-03-15 2010-07-01 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
DE102004025881A1 (de) 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
DE102005001784A1 (de) 2005-01-13 2006-10-05 Beiersdorf Ag Oligoribonukleotide zur Reduktion der Schweißbildung durch RNA-Interferenz
FR2885808B1 (fr) 2005-05-19 2007-07-06 Oreal Vectorisation de dsrna par des particules cationiques et utilisation topique.
CA2615323A1 (fr) 2005-06-06 2007-12-21 454 Life Sciences Corporation Sequencage d'extremites appariees
AU2006275579B2 (en) 2005-08-01 2012-10-04 Purdue Research Foundation Multivalent RNA nanoparticles for delivery of active agents to a cell
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 1本鎖環状rnaおよびその製造方法
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
WO2010080129A2 (fr) 2008-12-18 2010-07-15 Dicerna Pharmaceuticals, Inc. Agents allongés servant de substrats de dicer et procédés d'inhibition spécifique de l'expression d'un gène
WO2010084371A1 (fr) 2009-01-26 2010-07-29 Mitoprod Nouvelles molécules d'arn interférent circulaire
KR101938548B1 (ko) 2011-06-23 2019-01-15 (주)아모레퍼시픽 마이크로 rna를 포함하는 색소형성유전자 발현조절용 조성물
EP2765982A1 (fr) 2011-10-11 2014-08-20 Hans Kosak Diméthylsulfoxyde utilisé comme solvant pour des acides nucléiques
WO2013113326A1 (fr) * 2012-01-31 2013-08-08 Curevac Gmbh Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide
JP6284181B2 (ja) 2012-02-09 2018-02-28 国立研究開発法人理化学研究所 環状rna及びタンパク質の製造方法
CN108949772A (zh) 2012-04-02 2018-12-07 现代泰克斯公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
SG10201809817UA (en) 2012-05-25 2018-12-28 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
PT2893004T (pt) 2012-09-04 2019-01-21 Cellectis Recetor de antígeno quimérico de cadeia múltipla e utilizações do mesmo
DK2925866T3 (en) 2012-11-30 2018-10-29 Univ Aarhus CIRCULAR RNA FOR INHIBITING MICRO-RNA
EP2964234A4 (fr) 2013-03-09 2016-12-07 Moderna Therapeutics Inc Régions non traduites hétérologues pour arnm
DE102013005361A1 (de) 2013-03-28 2014-10-02 Eberhard Karls Universität Tübingen Medizinische Fakultät Polyribonucleotid
JP6625521B2 (ja) 2013-05-15 2020-01-08 リボカイン,エルエルシー 環状rnaの細胞内翻訳
AU2014306416B2 (en) 2013-08-16 2021-02-25 Translate Bio Ma, Inc. Compositions and methods for modulating RNA
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2015058069A1 (fr) * 2013-10-18 2015-04-23 Moderna Therapeutics, Inc. Compositions et procédés pour tolériser des systèmes cellulaires
DK4023249T3 (da) 2014-04-23 2025-01-13 Modernatx Inc Nukleinsyrevacciner
US10407683B2 (en) 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
EP3054017A1 (fr) 2015-02-03 2016-08-10 Johann Wolfgang Goethe-Universität, Frankfurt am Main ARN circulaire pour le diagnostic et traitement de maladies cardiovasculaires
MX367563B (es) 2015-03-20 2019-08-27 Unilever Nv Composición antitranspirante.
AU2016271519B2 (en) 2015-06-05 2021-09-02 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
AU2016286364B2 (en) 2015-06-30 2022-07-28 Ethris Gmbh ATP-binding cassette family coding polyribonucleotides and formulations thereof
CN108138201A (zh) * 2015-09-04 2018-06-08 托卡根公司 包含2a肽的重组载体
CN105664239B (zh) 2016-03-23 2018-08-07 成都交大麦迪克科技有限公司 一种自粘附皮肤修复水凝胶的制备方法
CA3028682A1 (fr) 2016-06-20 2017-12-28 Howard Y. Chang Arn circulaires et leur utilisation dans l'immunomodulation
CN106222174B (zh) * 2016-08-12 2020-08-04 青岛大学 circRNA CHIF核苷酸在治疗心脏疾病中的用途
AU2018251187B2 (en) 2017-04-14 2024-03-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
WO2018231990A2 (fr) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucléotides codant pour la méthylmalonyl-coa mutase
US11756183B2 (en) 2017-06-23 2023-09-12 Cornell University RNA molecules, methods of producing circular RNA, and treatment methods
MA51155A (fr) 2017-12-15 2020-10-21 Flagship Pioneering Innovations Vi Llc Compositions comprenant des polyribonucléotides circulaires et leurs utilisations
BR112020024292A2 (pt) 2018-06-06 2021-03-02 Massachusetts Institute Of Technology rna circular para translação em células eucarióticas
CN112567038A (zh) 2018-07-24 2021-03-26 旗舰创业创新第六有限责任公司 包含环状多核糖核苷酸的组合物及其用途
CN111603477B (zh) 2019-02-25 2023-06-02 中国科学院分子细胞科学卓越创新中心 环形rna在系统性红斑狼疮制备治疗药物中的应用
CA3128615A1 (fr) 2019-03-01 2020-09-10 Flagship Pioneering Innovations Vi, Llc Administration topique d'acides polyribonucleiques
IL285951B2 (en) 2019-03-01 2024-08-01 Flagship Pioneering Innovations Vi Llc Polyribonucleotides and their cosmetic uses
CN121081491A (zh) 2019-03-04 2025-12-09 旗舰创业创新第六有限责任公司 环状多核糖核苷酸及其药物组合物
EP3946466A2 (fr) 2019-03-25 2022-02-09 Flagship Pioneering Innovations VI, LLC Compositions comprenant des polyribonucléotides circulaires modifiés et utilisations associées
IL288284B2 (en) 2019-05-22 2024-06-01 Massachusetts Inst Technology Circular rna compositions and methods
CA3140205A1 (fr) 2019-06-14 2020-12-17 Alexandra Sophie DE BOER Arn circulaires pour therapie cellulaire
AU2020296190A1 (en) 2019-06-19 2022-01-06 Flagship Pioneering Innovations Vi, Llc Methods of dosing circular polyribonucleotides
WO2020257730A1 (fr) 2019-06-19 2020-12-24 Flagship Pioneering Innovations Vi, Llc Compositions comprenant des polyribonucléotides circulaires pour la modulation de protéine et leurs utilisations
EP4096681A1 (fr) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Administration de compositions comprenant des polyribonucléotides circulaires
US20230181620A1 (en) 2020-01-29 2023-06-15 Flagship Pioneering Innovations Vi, Llc Compositions for translation and methods of use thereof
EP4096715A1 (fr) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Compositions comprenant des polyribonucléotides linéaires pour la modulation de protéine et leurs utilisations
MX2022014653A (es) 2020-05-20 2023-02-16 Flagship Pioneering Innovations Vi Llc Composiciones de antigeno de coronavirus y sus usos.
EP4153152A1 (fr) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Compositions et procédés de production d'anticorps polyclonaux humains
CA3179444A1 (fr) 2020-05-20 2021-11-25 Avak Kahvejian Compositions immunogenes et leurs utilisations

Also Published As

Publication number Publication date
US20190307785A1 (en) 2019-10-10
US11160822B2 (en) 2021-11-02
SG11202005060YA (en) 2020-06-29
EP3724208A4 (fr) 2021-09-01
US20220023331A1 (en) 2022-01-27
JP2021508490A (ja) 2021-03-11
US20200306286A1 (en) 2020-10-01
IL316195A (en) 2024-12-01
US10953033B2 (en) 2021-03-23
EP3724208A1 (fr) 2020-10-21
IL275205B2 (en) 2025-03-01
AU2018385757B2 (en) 2023-10-19
US20210275565A1 (en) 2021-09-09
IL275205A (en) 2020-07-30
AU2018385757A1 (en) 2020-06-25
JP2026016607A (ja) 2026-02-03
US20240122959A1 (en) 2024-04-18
CN120774994A (zh) 2025-10-14
MX2020006150A (es) 2020-11-11
US20250381211A1 (en) 2025-12-18
US20230201241A1 (en) 2023-06-29
KR20200127152A (ko) 2020-11-10
CA3084824A1 (fr) 2019-06-20
CN111819185A (zh) 2020-10-23
US12357653B2 (en) 2025-07-15
US20230070937A1 (en) 2023-03-09
US11844759B2 (en) 2023-12-19
AU2024200298A1 (en) 2024-02-01
US12539309B2 (en) 2026-02-03
US20210161938A1 (en) 2021-06-03
US11058706B2 (en) 2021-07-13
JP2023126888A (ja) 2023-09-12
US11458156B2 (en) 2022-10-04
CN120737150A (zh) 2025-10-03
WO2019118919A1 (fr) 2019-06-20
BR112020011670A2 (pt) 2020-11-17
IL275205B1 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
EP3724208A4 (fr) Compositions comprenant des polyribonucléotides circulaires et leurs utilisations
EP3827084A4 (fr) Compositions comprenant des polyribonucléotides circulaires et utilisations associées
EP3419676A4 (fr) Compositions antimicrobiennes et leurs utilisations
EP3328199A4 (fr) Compositions antimicrobiennes et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA46990A (fr) Compositions de glp-1 et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3600273A4 (fr) Inhibiteurs de cd73 et leurs utilisations
EP3661563A4 (fr) Nanomatériaux biomimétiques et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
EP3472129A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA45943A (fr) Compositions ignifuges et leurs utilisations
EP3413816A4 (fr) Compositions hydratantes et utilisations associées
EP3370528A4 (fr) Compositions probiotiques et leurs utilisations
EP3790861A4 (fr) Compositions sénolytiques et utilisations associées
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
EP3349802A4 (fr) Dendrimères lipocationiques et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3471726A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3655043A4 (fr) Compositions topiques et leurs utilisations